FAS and colorectal cancer: In a Phase 1/2 trial in patients with advanced colorectal cancer (NCT00118989), curcumin was well tolerated up to 3.6 g/day and showed biological activity by modulating cancer-related biomarkers including cyclin D1, COX-2, and possibly FAS (Fuentes et al., 2017).